| + |
afimoxifene | down-regulates activity 
chemical inhibition
|
ESR2 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-258596 |
|
|
in vitro |
|
| pmid |
sentence |
| 9048584 |
In total 37 substances were tested for both ER subtypes (Fig. 3 and Table 1). In Fig. 3 several examples of typical competitor curves obtained are shown. In all cases monophasic curves were obtained for compounds with significant affinity. . The present study is the first in which the ligand binding properties of both ER subtypes are measured separately, and caution is needed when comparing RBAs from this study with the previous studies involving mixtures of ER subtypes. |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
afimoxifene | down-regulates activity
chemical inhibition
|
ESR1 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-258595 |
|
|
in vitro |
|
| pmid |
sentence |
| 9048584 |
In total 37 substances were tested for both ER subtypes (Fig. 3 and Table 1). In Fig. 3 several examples of typical competitor curves obtained are shown. In all cases monophasic curves were obtained for compounds with significant affinity. . The present study is the first in which the ligand binding properties of both ER subtypes are measured separately, and caution is needed when comparing RBAs from this study with the previous studies involving mixtures of ER subtypes. |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
afimoxifene | up-regulates activity 
chemical activation
|
ESR1 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-258594 |
|
|
in vitro |
|
| pmid |
sentence |
| 9048584 |
In total 37 substances were tested for both ER subtypes (Fig. 3 and Table 1). In Fig. 3 several examples of typical competitor curves obtained are shown. In all cases monophasic curves were obtained for compounds with significant affinity. . The present study is the first in which the ligand binding properties of both ER subtypes are measured separately, and caution is needed when comparing RBAs from this study with the previous studies involving mixtures of ER subtypes. |
|
| Publications: |
1 |
Organism: |
In Vitro |
3.0
afimoxifene
